TORM plc Chief Financial Officer Kim Balle filed a Form 4 with the SEC on September 24, 2026, disclosing the sale of 42,533 Class A Common Shares across three transactions between September 18 and September 22, 2026.
A Form 4 filed on September 24, 2026 discloses changes in beneficial ownership of Class A ordinary share RSUs by Chen Yang Luke, a director of 111, Inc. (NASDAQ:YI), covering transactions dated as early as September 8, 2023 through September 23, 2026.
IDT Corporation filed a Form 8-K with the SEC on September 23, 2026, disclosing that its Board of Directors declared a quarterly cash dividend of $0.07 per share, payable on October 14, 2026.
News Corporation filed a Form 8-K on September 24, 2026, reporting that it provided share repurchase transaction disclosures to the Australian Securities Exchange, with the date of earliest event reported as September 23, 2026.
AMC Entertainment Holdings, Inc. filed a Form 8-K on September 24, 2026, reporting that on September 23, 2026, it priced $2,000 million in 8.875% first lien notes due 2031 and $850 million in first lien term loans as part of a broader debt refinancing …
First Merchants Corporation filed a current report on Form 8-K dated September 23, 2026, disclosing its entry into an underwriting agreement and the pricing of a $100,000,000 subordinated notes offering.
Lantern Pharma Inc. filed a Form 8-K with the SEC on September 24, 2026, disclosing that the company hosted a live webinar on September 23, 2026, to discuss its Open-Medicine AI multi-agentic AI platform for drug development.
Jaguar Health, Inc. filed a Form 8-K on September 24, 2026, disclosing that on September 23, 2026, the company entered into exchange agreements with Streeterville Capital, LLC to issue 547,898 shares of common stock in exchange for a reduction in the outstanding balance of …
Kyverna Therapeutics, Inc. filed a Form 8-K on September 24, 2026, disclosing positive one-year data from its registrational trial KYSA-8 and positive longer-term follow-up data from the Phase 2 portion of its registrational trial KYSA-6, both evaluating miv-cel (mivocabtagene autoleucel, KYV-101).
TruGolf Holdings, Inc. filed a Form 8-K with the SEC on September 24, 2026, reporting the September 22, 2026 resignation of Christopher Jones from all roles, the execution of a Separation and Settlement Agreement, and the appointment of Jay Heller to the Company's Board …